Comsa has landed in the United States through its subsidiary Eolis, which specializes in bespoke air conditioning systems and focuses on creating reliable and efficient industrial environments that result from the design, manufacture, installation, and commissioning of these air conditioning systems.
This business unit is part of the Bio&Pharma division of the Catalan engineering and construction group that was created under that name in 2021, although Comsa has more than 60 years of experience in this field, in which the company is growing in various ways, as company sources have told elEconomista.es.
Over the last decade, sales have grown from €10 million in 2013 to over €40 million in 2022, and this is one of the levers with which Comsa expects to reach €1,000 million in total group sales in 2025, compared to €886 in the previous year, 16.8% more than in 2021.
Bio&Pharma’s current workforce is around 80 people in Spain and more than 300 in various countries in Latin America and North Africa. And it is that in the last 10 years, the company has consolidated its presence in the Americas, particularly in Mexico, Colombia, Paraguay, and Uruguay.
In Mexico, the company is active in the pharmaceutical and industrial sectors through its subsidiary Eolis. Headquartered in Mexico City, Eolis has an air conditioning factory in Puebla and a commercial office in Guadalajara.
In the United States, Eolis is currently focused on the manufacture of air conditioning and air handling systems for customers in the automotive sector and for industry in general. The companies there usually have their own installers and have therefore decided to market high-quality devices at very competitive prices for the time being, the company emphasizes.
Reference in Spain
Comsa Bio&Pharma is the only company in Spain that carries out comprehensive projects in the life sciences sector, from civil works to mechanical, electrical and control system installations, with clients from the pharmaceutical, hospital, veterinary, cosmetic, food and technology sectors. It includes, among other things, facilities for active ingredients through to research and vaccine production centers.
His projects in recent years have included the new Alter production facility in Meco (Madrid); the new building and cosmetics plant for Natura Bissé in Cerdanyola del Vallès (Barcelona); a sterile liquids plant for Pharmaloop (Grupo Salvat) in Madrid and the new laboratory building for Kern Pharma in Terrassa (Barcelona).
In the technology sector, Comsa Bio&Pharma is already running some high-tech projects, such as AnaFocus, a company specializing in CMOS image sensors and image processing systems for industrial, scientific, medical and high-end surveillance applications.
In addition, the company has carried out initial projects for technology companies in the aerospace and microprocessor sectors, thereby positioning itself in this growth segment.
